Article
Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective.
Kidney international - 1 Jul 2018
Alric Laurent, Ollivier-Hourmand Isabelle, Bérard Emilie, Hillaire Sophie, Guillaume Maeva, Vallet-Pichard Anais, Bernard-Chabert Brigitte, Loustaud-Ratti Veronique, Bourlière Marc, de Ledinghen Victor, Fouchard-Hubert Isabelle, Canva Valerie, Minello Anne, Nguyen-Khac Eric, Leroy Vincent, Saadoun David, Trias Dominique, Pol Stanislas, Kamar Nassim
Abstract excerpt
Patients with advanced chronic kidney disease who receive direct-acting antiviral drugs require special consideration regarding comorbid conditions. Here we assessed the efficacy and safety of grazoprevir plus elbasvir in 93 patients infected with HCV genotype 1 or 4 and with advanced chronic kidney disease in a non-randomized, multicenter, nationwide observational survey. Twenty patients with HCV genotype 1a, 51...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.